Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA cancer vaccine.
🌍 Cross-language spread
PULSE detected this story across 5 language editions of the world's news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Coverage from outlets including STAT, Reuters, Bloomberg, The Washington Post, Yahoo Finance, CNBC, Ars Technica, and the Wall Street Journal details that Moderna and Merck have announced the success of their mRNA cancer vaccine in a late-stage melanoma trial. According to the reports, the personalized vaccine met its goals in a large, Phase 3 melanoma trial by helping cut melanoma recurrence. The announcement has triggered significant financial market activity, with Moderna stock surging and broader mRNA vaccine stocks also rising following the news. Financial reports from Bloomberg specify that Moderna experienced a 160% surge that burned short sellers and resulted in a painful five billion dollar loss.
Yahoo Finance and other financial publications frame the trial results as a landmark moment for cancer treatment and stock performance. Outlets like CNBC and Ars Technica emphasize that this represents the first successful late-stage trial for a personalized cancer vaccine utilizing mRNA technology developed jointly by Moderna and Merck. The context provided by the coverage positions this development within the broader evolution of mRNA technology, extending its application beyond infectious diseases into oncology. The Wall Street Journal and STAT note that the success in this late-stage melanoma trial marks a critical milestone for the field of personalized cancer therapeutics, drawing intense interest from investors, medical researchers, and patients alike.
Coverage does not yet specify the exact regulatory timeline or the specific dates for future data presentations, though the companies have established the trial's success. Observers and market analysts will monitor how regulatory bodies respond to these Phase 3 results and whether the personalized melanoma vaccine will advance toward formal approval applications based on the current trial data.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 90d ago.
Quick answers
Which companies announced the melanoma vaccine trial success?
Moderna and Merck announced the success.
What type of trial was the melanoma vaccine tested in?
The vaccine was tested in a large, late-stage Phase 3 melanoma trial.
How did financial markets react to the announcement?
Moderna stock surged, resulting in a 160 percent surge and a five billion dollar loss for short sellers, while other mRNA vaccine stocks also rose.
Coverage (12)
- From Covid to Cancer: How Moderna’s Stock Jumped 177% in a Day The New York Times · 90d ago
- Moderna pins hopes on mRNA ‘game-changer’ for cancer vaccines Financial Times · 90d ago
- Moderna and Merck shares soar on mRNA cancer vaccine Axios · 90d ago
- Moderna stock surges as melanoma vaccine trial shows "landmark moment" Yahoo Finance · 90d ago
- Moderna’s 160% Surge Burns Shorts in ‘Painful’ $5 Billion Loss bloomberg.com · 90d ago
- mRNA Vaccine Stocks Rise on Moderna-Merck Success WSJ · 90d ago
- mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say Ars Technica · 90d ago
- Merck, Moderna say melanoma vaccine meets goals in large trial Reuters · 91d ago
- Cancer treatment could face landmark moment with promising vaccine The Washington Post · 91d ago
- Moderna-Merck MRNA Shot Helped Cut Melanoma Recurrence in Big Trial Bloomberg.com · 91d ago
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com · 91d ago
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial STAT · 91d ago
Topics
Related trends
The US flu season is off to a very early start. It’s targeting the South and West now
The U.S. flu season is off to a very early start, with cases surging in the South and West.
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
First measles case confirmed in Mahoning County
Mahoning County Public Health confirmed Ohio's first measles case in Mahoning County, a resident who tested positive, as officials track exposures and warn of symptoms.
Moderna swings to profit as momentum for cancer vaccine builds
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
New cancer treatment approach could help immune cells fight tumors longer
Researchers have identified a way to utilize p53 activation to enhance the potency and longevity of immune cells targeting solid tumors.